Scarica l'app Stockscreener
31.56
0.54%
0.17
Dopo l'orario di chiusura:
31.56
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$31.39
Aprire:
$31.07
Volume 24 ore:
167.10K
Relative Volume:
1.21
Capitalizzazione di mercato:
$499.19M
Reddito:
-
Utile/perdita netta:
$-61.23M
Rapporto P/E:
-2.3344
EPS:
-13.5194
Flusso di cassa netto:
$22.49M
1 W Prestazione:
-7.20%
1M Prestazione:
-10.80%
6M Prestazione:
+74.46%
1 anno Prestazione:
+86.30%
Intervallo 1D:
$29.31
$31.58
Intervallo di 1 settimana:
$29.31
$34.69
Portata 52W:
$7.75
$39.70
Assembly Biosciences Inc Stock (ASMB) Company Profile
Nome
Assembly Biosciences Inc
Settore
Industria
Telefono
(833) 409-4583
Indirizzo
TWO TOWER PLACE, SOUTH SAN FRANCISCO
Confronta ASMB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ASMB
Assembly Biosciences Inc
|
31.56 | 496.50M | 0 | -61.23M | 22.49M | -13.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-24 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-08-18 | Ripresa | H.C. Wainwright | Buy |
| 2025-03-25 | Iniziato | Guggenheim | Buy |
| 2024-09-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-09-13 | Iniziato | H.C. Wainwright | Neutral |
| 2021-09-02 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-03-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-06 | Downgrade | Jefferies | Buy → Hold |
| 2020-10-19 | Iniziato | Truist | Buy |
| 2019-10-16 | Iniziato | Mizuho | Buy |
| 2018-11-19 | Iniziato | Leerink Partners | Outperform |
| 2018-10-08 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-08-08 | Iniziato | Robert W. Baird | Outperform |
| 2018-04-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Neutral |
| 2017-11-08 | Iniziato | Jefferies | Buy |
| 2017-05-30 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Assembly Biosciences Inc Borsa (ASMB) Ultime notizie
How strong is Assembly Biosciences Inc. stock revenue growthWeekly Profit Recap & Precise Trade Entry Recommendations - ulpravda.ru
How Assembly Biosciences Inc. stock reacts to global recession fearsPrice Action & Advanced Technical Signal Analysis - ulpravda.ru
Why Assembly Biosciences Inc. (V7B) stock is a must watch ticker2025 Stock Rankings & Consistent Growth Equity Picks - ulpravda.ru
Is Assembly Biosciences Inc. stock attractive after correction2025 AllTime Highs & Short-Term Trading Opportunity Alerts - ulpravda.ru
What risks investors should watch in Assembly Biosciences Inc. stockMarket Risk Analysis & Weekly High Conviction Ideas - ulpravda.ru
Why Assembly Biosciences Inc. stock remains a top recommendation2026 world cup usa national team third place match star players low block defense winner prediction guide - ulpravda.ru
(ASMB) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Assembly Biosciences (NASDAQ:ASMB) Stock Price Up 4% – Time to Buy? - Defense World
Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
ASMB Stock Price, Forecast & Analysis | ASSEMBLY BIOSCIENCES INC (NASDAQ:ASMB) - Chartmill
Assembly Biosciences (NASDAQ:ASMB) Trading 4% HigherHere's What Happened - MarketBeat
After 25 Years, Recurrent Genital Herpes Treatment Gains Corporate Partner - Vax-Before-Travel
Gilead Sciences exercises option to license Assembly Biosciences Helicase-Primase Inhibitor programs for... - Medical Dialogues
Ellsworth Advisors LLC Acquires New Holdings in Assembly Biosciences, Inc. $ASMB - Defense World
Assembly Biosciences stock jumps after Wall Street says Gilead opt-in 'significantly de-risks' genital herpes programs - MSN
Technical Reactions to ASMB Trends in Macro Strategies - Stock Traders Daily
With 32% ownership, Assembly Biosciences, Inc. (NASDAQ:ASMB) has piqued the interest of institutional investors - Yahoo Finance
Assembly Biosciences price target raised to $40 from $29 at Mizuho - MSN
Assembly Biosciences (ASMB) price target increased by 24.84% to 48.70 - MSN
Assembly Biosciences (NASDAQ:ASMB) Stock Price Down 6%What's Next? - MarketBeat
GILD Exercises Option to License Assembly Bio's Herpes Programs - Eastern Progress
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes - BioSpace
Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes - Sahm
Assembly Biosciences (NASDAQ:ASMB) Receives Buy Rating from HC Wainwright - Defense World
Gilead opt-in ‘significantly de-risks’ Assembly pipeline, says HC Wainwright - MSN
Gilead exercises option for Assembly Bio’s herpes treatment programs By Investing.com - Investing.com South Africa
Gilead Sciences (GILD) Licenses Assembly Bio's Herpes Drug Progr - GuruFocus
HC Wainwright & Co. Reiterates Assembly Biosciences (ASMB) Buy Recommendation - Nasdaq
Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs - Asianet Newsable
Assembly Biosciences (NASDAQ:ASMB) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Assembly Biosciences rises as Gilead opts to license co's HSV therapies - TradingView — Track All Markets
ASMB: HC Wainwright & Co. Reiterates Buy Rating with $50 PT | AS - GuruFocus
Gilead exercises license for Assembly Biosciences herpes programs - Seeking Alpha
Assembly Biosciences' (ASMB) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Program - PharmiWeb.com
Gilead pays $35M to license pair of HSV assets from Assembly Bio pact - Fierce Biotech
Assembly Biosciences (ASMB) Gains Momentum with Gilead Licensing Deal - GuruFocus
Gilead exercises option for Assembly Bio’s herpes treatment programs - Investing.com
Gilead exercises option for Assembly Bio's herpes treatment programs - StreetInsider
Assembly Biosciences (ASMB) Price Target Increased by 24.84% to 48.70 - Nasdaq
Financial Analysis: Teva Pharmaceutical Industries (NYSE:TEVA) versus Assembly Biosciences (NASDAQ:ASMB) - Defense World
Can Assembly Biosciences Inc. stock beat analyst upgradesTrade Risk Assessment & Fast Entry Momentum Alerts - Улправда
Assembly Biosciences announces interim results from ABI-1179, ABI-5366 trials - MSN
How Assembly Biosciences Inc. stock performs in rising dollar environmentEntry Point & Reliable Price Breakout Alerts - Улправда
How resilient is Assembly Biosciences Inc. stock in market downturnsEarnings Summary Report & Scalable Portfolio Growth Methods - Улправда
Why Assembly Biosciences Inc. stock could see breakout soon2025 Trade Ideas & Risk Managed Trade Strategies - Улправда
Recap Report: How Assembly Biosciences Inc. stock performs in rising dollar environmentQuarterly Trade Report & Community Verified Watchlist Alerts - Улправда
Can Assembly Biosciences Inc. stock resist market sell offsJuly 2025 PreEarnings & Real-Time Volume Analysis Alerts - Улправда
Assembly Biosciences Earnings Notes - Trefis
Assembly Biosciences completes key phase 1a study on ABI-6250 - MSN
Assembly Biosciences (NASDAQ:ASMB) Stock Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Assembly Biosciences Inc Azioni (ASMB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):